SGLT2 inhibitors are known not only to improve cardiac function and metabolism, but also to promote weight loss by reducing visceral fat depots and to attenuate the obesity-induced inflammatory response and insulin resistance by modulating the activity of M2 macrophages (109, 110). The gene discussed is SLC5A2; the disease is obesity due to melanocortin 4 receptor deficiency.